Screener
Equillium
EQEquillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory disorders.
$111.28M+48.4%
Earnings
Next report
Nov 12, 2026 (In 1 week)EPS estimate-$0.05
Competitors
Profile
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory disorders. The company leverages its expertise in immunology to advance a pipeline of therapeutic candidates targeting unmet medical needs in gastroenterology, dermatology, and pulmonology.
Competitive position
Equillium is an emerging innovator in the autoimmune space, utilizing selective AhR modulation and multi-cytokine inhibition technologies.
GeographiesUnited States, Australia
Customer segmentsPharmaceutical companies
Business modelR&D, IP Licensing
SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Raw material suppliers
CustomersSpecialty pharmacies, Hospitals, Physicians, Large pharmaceutical partners
CountryUnited States of America
Listed2018
Employees44.0
CEOBruce D. Steel
SectorHealthcare
IndustryBiotechnology
Websiteequilliumbio.com
FilingsSEC EDGAR
FAQ
- What is Equillium's market cap?
- Equillium (EQ) has a market capitalization of $111.3M and trades on NASDAQ.
- Who are Equillium's competitors?
- Equillium's key competitors include Dermavant Sciences, ALX Oncology Holdings Inc. Common Stock, Compass Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Equillium have?
- Equillium's subsidiaries include Ariagen, Inc., Bioniz Therapeutics, Inc., Equillium Australia Pty LTD.
- Where is Equillium headquartered?
- Equillium is headquartered in United States of America and employs approximately 44 people. It has been publicly traded since 2018.